Eris Lifesciences Ltd-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Eris Lifesciences Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014224
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:29
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:インド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Eris Lifesciences Ltd (Eris Lifesciences) is a pharmaceutical company that manufactures and commercializes generics products. The company through its divisions provides wide range of products including Maxum, Decal, Eritel H, Eritel CH 80 LS, Glimisave Max Forte 1, Mac Rabonik Plus, Vomisave Syrup, Nikomox CV Dry Syrup and others. Eris Lifesciences offer products in the therapeutic areas of cardiology, gastroenterology, orthopedics and diabetes. It offers products in the form of tablets, syrups and capsules. The company has its manufacturing facility located at Assam, India. Eris Lifesciences is headquartered in Ahmedabad, Gujarat, India.

Eris Lifesciences Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Eris Lifesciences Ltd, Medical Devices Deals, 2011 to YTD 2017 10
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Eris Lifesciences to Acquire Branded Generics Business from Strides Shasun for USD76.7 Million 12
Eris Lifesciences Acquires 40 Trademarks from Amay Pharma for USD5 Million 14
Private Equity 15
ChrysCapital Invests In Eris Lifesciences 15
Licensing Agreements 16
Aprica Healthcare Enters into Licensing Agreement with Eris Lifesciences 16
Equity Offering 17
Eris Lifesciences Raises USD270 Million in IPO 17
Acquisition 18
Eris Lifesciences Acquires UTH Healthcare for USD2 Million 18
Eris Lifesciences Acquires Additional 14% Stake in Kinedex Healthcare for USD2 Million 19
Eris Lifesciences Acquires 61.48% Stake in Kinedex Healthcare for USD9.2 Million 20
Eris Lifesciences Acquires Aprica Healthcare 21
ChrysCapital May Sell its Stake in Eris Lifesciences 22
Nrim May Acquire Additional Stake in Kinedex Healthcare 23
Nrim Invests in Kinedex Healthcare 24
Eris Lifesciences Ltd – Key Competitors 25
Eris Lifesciences Ltd – Key Employees 26
Eris Lifesciences Ltd – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Other Significant Developments 28
Aug 17, 2017: Eris Lifesciences Announces the Dhifting of the Registered Office of the Company 28
Appendix 29
Methodology 29
About GlobalData 29
Contact Us 29
Disclaimer 29

List of Tables
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Eris Lifesciences Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Eris Lifesciences Ltd, Medical Devices Deals, 2011 to YTD 2017 10
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Eris Lifesciences to Acquire Branded Generics Business from Strides Shasun for USD76.7 Million 12
Eris Lifesciences Acquires 40 Trademarks from Amay Pharma for USD5 Million 14
ChrysCapital Invests In Eris Lifesciences 15
Aprica Healthcare Enters into Licensing Agreement with Eris Lifesciences 16
Eris Lifesciences Raises USD270 Million in IPO 17
Eris Lifesciences Acquires UTH Healthcare for USD2 Million 18
Eris Lifesciences Acquires Additional 14% Stake in Kinedex Healthcare for USD2 Million 19
Eris Lifesciences Acquires 61.48% Stake in Kinedex Healthcare for USD9.2 Million 20
Eris Lifesciences Acquires Aprica Healthcare 21
ChrysCapital May Sell its Stake in Eris Lifesciences 22
Nrim May Acquire Additional Stake in Kinedex Healthcare 23
Nrim Invests in Kinedex Healthcare 24
Eris Lifesciences Ltd, Key Competitors 25
Eris Lifesciences Ltd, Key Employees 26
Eris Lifesciences Ltd, Subsidiaries 27

★海外企業調査レポート[Eris Lifesciences Ltd-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Sareum Holdings Plc (SAR):製薬・医療:M&Aディール及び事業提携情報
    Summary Sareum Holdings Plc (Sareum) is a drug discovery and development company that produces targeted small molecule therapeutics for treating cancer and autoimmune diseases. The drug research programs of the company are based on its proprietary drug discovery technology, Sareum Kinase Inhibitor L …
  • Pantheon Resources plc (PANR):企業の財務・戦略的SWOT分析
    Summary Pantheon Resources Plc (Pantheon Resources) is an oil and gas exploration and production company. It explores, develops and produces crude oil and natural gas resource properties. The company invests in oil and gas exploration and development. It operates hydrocarbon producing basins onshore …
  • Recipharm AB (RECI B):企業の財務・戦略的SWOT分析
    Recipharm AB (RECI B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Renova Energia SA (RNEW11):企業の財務・戦略的SWOT分析
    Renova Energia SA (RNEW11) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Philippine National Bank:企業の戦略・SWOT・財務情報
    Philippine National Bank - Strategy, SWOT and Corporate Finance Report Summary Philippine National Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • The Mosaic Company:企業の戦略・SWOT・財務分析
    The Mosaic Company - Strategy, SWOT and Corporate Finance Report Summary The Mosaic Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Sete Brasil Participacoes SA:企業の戦略的SWOT分析
    Sete Brasil Participacoes SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Wipro Ltd:企業のM&A・事業提携・投資動向
    Wipro Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Wipro Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capita …
  • Largo Resources Ltd.:企業のM&A・事業提携・投資動向
    Largo Resources Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Largo Resources Ltd. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A …
  • Ilmarinen Mutual Pension Insurance Co-エネルギー分野:企業M&A・提携分析
    Summary Ilmarinen Mutual Pension Insurance Company (IMPIC) is a financial service provider that offers pension insurance and related services. The company provides services for private customers, which include information on pensions, retiring, pensioner, forms and brochures, pensioner's tax card, a …
  • InviCRO LLC:医療機器:M&Aディール及び事業提携情報
    Summary InviCRO LLC (InviCRO) a subsidiary of Konica Minolta Inc, is a provider of image informatics, engineering and operational services in translational drug discovery and development. The company developed VivoQuant, a DICOM compliant post-processing suite for image data combining fundamental vi …
  • 3-D Matrix Ltd (7777):企業の財務・戦略的SWOT分析
    3-D Matrix Ltd (7777) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Mitsubishi Chemical Holdings Corporation:企業の戦略・SWOT・財務分析
    Mitsubishi Chemical Holdings Corporation - Strategy, SWOT and Corporate Finance Report Summary Mitsubishi Chemical Holdings Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Yanbu National Petrochemicals Co (2290):企業の財務・戦略的SWOT分析
    Summary Yanbu National Petrochemicals Co (YANSAB), a subsidiary of Saudi Basic Industries Corp is a manufacturer and distributor of petrochemical products. The company offers products such as ethylene, linear density polyethylene, polypropylene, butene 1, ethylene glycol, polyethylene, butene 2, MTB …
  • Implanet SA (IMPL):企業の財務・戦略的SWOT分析
    Summary Implanet SA (Implanet) is a medical device company that designs, manufactures and markets orthopaedic products. The company offers spine, knee and arthroscopy products. Its spine products are used for the treatment of spinal disorders and spinal fusion surgery. Implanet offers resorbable anc …
  • Synedgen Inc-製薬・医療分野:企業M&A・提携分析
    Summary Synedgen Inc (Synedgen) is a biotechnology company that focuses on the discovery and development of polysaccharide-based drugs. The company’s pipeline products include SYGN 113; SYGN 115; SYGN 146; SYGN 303; SYGN 313 and SYGN 399 among others. Synedgen develops products for the treatment of …
  • Standard Chartered Plc:企業のM&A・事業提携・投資動向
    Standard Chartered Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Standard Chartered Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …
  • Ambry Genetics Corp-製薬・医療分野:企業M&A・提携分析
    Summary Ambry Genetics Corp (Ambry Genetics) is a biotechnology company that offers genetic testing services. The company offers clinical diagnostics services, which include tests, forms, billing, managed care, order kits, reporting, licenses, family studies program, variant classification and secur …
  • Magnora ASA (SEVAN):企業の財務・戦略的SWOT分析
    Summary Magnora ASA (Magnora) is an oil and gas company that offers engineering, design, and project execution of floating units for offshore applications. The company's floating production units include Hummingbird spirit, Voyageur spirit, Piranema spirit, Goliat FPSO and Western Isles FPSO, among …
  • Absorption Systems LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Absorption Systems LLC (Absorption Systems), formerly Absorption Systems LP is a pre-clinical contract research organization that develops and implements research tools. The organization offers preclinical testing of biologics, drugs, and medical devices. It also develops and implements rese …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆